Literature DB >> 30194475

Long-term symptom improvement and patient satisfaction after AV-node ablation vs. pulmonary vein isolation for symptomatic atrial fibrillation: results from the German Ablation Registry.

Kristina Wasmer1, M Hochadel2, H Wieneke3, S G Spitzer4,5, J Brachmann6, F Straube7, J Tebbenjohanns8, G Groschup9, A Heisel10, T Lewalter11, J Senges2, L Eckardt12.   

Abstract

BACKGROUND: We aimed to compare patient characteristics and outcome of patients who had either undergone pulmonary vein isolation (PVI) or AV-node ablation (AVN) to control AF-related symptoms.
METHODS: From the German Ablation Registry, we analyzed data of 4444 patients (95%) who had undergone PVI and 234 patients (5%) with AVN.
RESULTS: AVN patients were on average 10 years older than PVI patients (71 ± 10 vs. 61 ± 10 years, p < 0.001) with 33% aged > 75 years. AVN patients had significantly more cardiovascular comorbidities (diabetes 21% vs. 8%, renal insufficiency 24% vs. 3%, underlying heart disease 80% vs. 36%, severely reduced left ventricular function 28% vs. 1%, all p < 0.001). Significantly more PVI patients had paroxysmal AF (63% vs. 18%, p < 0.001), and more AVN patients had long-standing persistent AF (44% vs. 7%, p < 0.001). At 1-year follow-up, mortality in the AVN group was much higher (Kaplan-Meier estimates 9.8% vs. 0.5%). 20% of PVI patients had undergone another ablation vs. 3% AVN patients (p < 0.001). Symptomatic improvement was equally achieved in about 80%. Re-hospitalization for cardiovascular reasons occurred significantly more often in PVI vs. AVN patients (31% vs. 18%, p < 0.001).
CONCLUSION: In the large German Ablation Registry, AVN ablation was performed much less frequently than PVI for symptomatic treatment of AF and typically in older patients with more comorbidity. Symptomatic improvement was similar in both groups. Hospitalizations for cardiovascular reasons were lower in AVN patients despite older age and more cardiovascular comorbidities. 20% of PVI patients had undergone at least one re-ablation.

Entities:  

Keywords:  AV-node ablation; Atrial fibrillation; Pulmonary vein isolation; Symptomatic improvement

Mesh:

Year:  2018        PMID: 30194475     DOI: 10.1007/s00392-018-1368-2

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  5 in total

Review 1.  Association between atrial fibrillation and Helicobacter pylori.

Authors:  Cecilia Tetta; Amalia Ioanna Moula; Francesco Matteucci; Orlando Parise; Bart Maesen; Daniel Johnson; Mark La Meir; Sandro Gelsomino
Journal:  Clin Res Cardiol       Date:  2019-02-08       Impact factor: 5.460

2.  Ablation of paroxysmal and persistent atrial fibrillation in the very elderly real-world data on safety and efficacy.

Authors:  Kevin Willy; Kristina Wasmer; Dirk G Dechering; Julia Köbe; Philipp S Lange; Nils Bögeholz; Christian Ellermann; Florian Reinke; Gerrit Frommeyer; Lars Eckardt
Journal:  Clin Cardiol       Date:  2020-10-19       Impact factor: 2.882

3.  Catheter ablation of supraventricular tachycardia in patients with and without structural heart disease: insights from the German ablation registry.

Authors:  Charlotte Eitel; Hüseyin Ince; Johannes Brachmann; Karl-Heinz Kuck; Stephan Willems; Stefan G Spitzer; Juergen Tebbenjohanns; Leon Iden; Florian Straube; Matthias Hochadel; Jochen Senges; Roland R Tilz
Journal:  Clin Res Cardiol       Date:  2021-06-09       Impact factor: 6.138

4.  Safety and patient-reported outcomes in index ablation versus repeat ablation in atrial fibrillation: insights from the German Ablation Registry.

Authors:  Shinwan Kany; Johannes Brachmann; Thorsten Lewalter; Karl-Heinz Kuck; Dietrich Andresen; Stephan Willems; Ellen Hoffmann; Lars Eckardt; Dierk Thomas; Matthias Hochadel; Jochen Senges; Andreas Metzner; Andreas Rillig
Journal:  Clin Res Cardiol       Date:  2020-10-28       Impact factor: 5.460

Review 5.  Pulmonary vein isolation treats symptomatic AF in a patient with Lamin A/C mutation: case report and review of the literature.

Authors:  Ann-Kathrin Rahm; Patrick Lugenbiel; Marco Ochs; Benjamin Meder; Dierk Thomas; Hugo A Katus; Eberhard Scholz
Journal:  Clin Res Cardiol       Date:  2020-03-06       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.